Julia Jones is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6560 Fannin St Ste 802
Houston, TX 770302726
Telephone
713-363-7150Registry record last updated 21 Jul 2022.
Clinical trials
- Exercise Prehabilitation in Congenital Heart Disease
Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
51 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202540 payments
- ABBVIE INC.Program year202526 payments
- Lundbeck LLCProgram year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
85.3%Neuromuscular Blocker85.1%Onabotulinumtoxina100%Part B, office-administered≥22 patientsMuscle Relaxant0.2%Cyclobenzaprine Hcl61%Methocarbamol39%Part D<11 patientsNervous system
13.4%Gabapentinoids3.3%Gabapentin82%Pregabalin18%Part D≥124 patientsSerotonin-1b and Serotonin-1d Receptor Agonist2.8%Rizatriptan42%Sumatriptan Succinate41%Eletriptan Hbr6%Sumatriptan5%Naratriptan Hcl3%Zolmitriptan Odt3%Part D<11 patients+ 20 more classes in this area
Cancer & immunology
0.6%Nonsteroidal Anti-inflammatory Drug0.3%Celecoxib100%Part D≥16 patientsOther immunostimulants0.2%Copaxone100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”